Please use this identifier to cite or link to this item:
|Scopus||Web of Science®||Altmetric|
|Title:||Serelaxin: a novel therapeutic for vascular diseases|
|Citation:||Trends in Pharmacological Sciences, 2016; 37(6):498-507|
|Chen Huei Leo, Maria Jelinic, Hooi Hooi Ng, MarianneTare, Laura J.Parry|
|Abstract:||Vascular dysfunction is an important hallmark of cardiovascular disease. It is characterized by increased sensitivity to vasoconstrictors, decreases in the endothelium-derived vasodilators nitric oxide (NO) and prostacyclin (PGI2), and endothelium-derived hyperpolarization (EDH). Serelaxin (recombinant human relaxin) has gained considerable attention as a new vasoactive drug, largely through its beneficial therapeutic effects in acute heart failure. In this review we first describe the contribution of endogenous relaxin to vascular homeostasis. We then provide a comprehensive overview of the novel mechanisms of serelaxin action in blood vessels that differentiate it from other vasodilator drugs and explain how this peptide could be used more widely as a therapeutic to alleviate vascular dysfunction in several cardiovascular diseases.|
|Keywords:||Serelaxin; vascular dysfunction; endothelium; prostanoids; nitric oxide|
|Rights:||© 2016 Published by Elsevier Ltd.|
|Appears in Collections:||Pharmacology publications|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.